Tradestie Institutional Equity Comparison Engine

NKTX vs SANA โ€” Head-to-Head Terminal

6-dimension institutional benchmarking across valuation, multi-year operating margins, normalized momentum, and dealer gamma corridors.

Market Close: 2026-11-16 Buy Verdict Report Ask Alpha

Pillar 1 Executive Scorecard & Category Winner Tally

NKTX Overall Edge

NKTX Captures Institutional Edge (3โ€“0 Pillars ยท 3โ€“2 Matrix Metrics)

Tradestie Institutional Equity Comparison Engine assigns the overall head-to-head edge to Nkarta, Inc. Common Stock (NKTX) driven by superior Growth & Margin, Momentum & Technical, Options & Structure. Fundamentally, NKTX trades at N/M Forward P/E with 0.0% operating margin (+0.0% YoY revenue) versus SANA at N/M Forward P/E and 0.0% operating margin (+0.0% YoY). In options structure, NKTX sits in UNCLASSIFIED (<1st %ile IV; Dealer Gamma Walls on Pro) against SANA sits in BREAKDOWN (4th %ile IV; Dealer Gamma Walls on Pro).

Valuation Winner Tie
NKTX N/M vs SANA N/M Fwd P/E
Growth & Margin Winner NKTX
Op Margin 0.0% vs 0.0% ยท YoY +0.0% vs +0.0%
Momentum & Technical Winner NKTX
1Y -35.6% vs -48.6% ยท 52W Pos 4% vs 1%
Options & Structure Winner NKTX
UNCLASSIFIED (<1st %ile IV) vs BREAKDOWN (4th %ile IV)
NKTX NASDAQ
Nkarta, Inc. Common Stock
Pharmaceutical Preparations
$1.21
+1.68% 1D
Market Cap $85.2M
1M Return -32.78%
1Y Return -35.64%
Forward P/E N/M
Unified AI Score
50.5 / 100 HOLD
Tech 43.0 Fund 59.0 Flow 70.0 Mom 60.0
SANA NASDAQ
Sana Biotechnology, Inc. Common Stock
Biological Products, (No Disgnostic Substances)
$1.88
-6.93% 1D
Market Cap $605.3M
1M Return -17.18%
1Y Return -48.63%
Forward P/E N/M
Unified AI Score
44.3 / 100 HOLD
Tech 33.0 Fund 51.0 Flow 66.0 Mom 60.0

Pillar 2 Normalized Relative Return Performance (% Indexed to 0%)

1Y Indexed Return: NKTX -35.64% SANA -48.63% Spread: +12.99 pp (NKTX Lead)

Pillar 3 Operating Profitability Benchmark (Trailing 12-Month)

Split-Invariant Revenue ($B) & Operating Margin (%)
NKTX TTM Op. Margin: 0.0% SANA TTM Op. Margin: 0.0%
Standardized multi-year USD domestic revenue schedules are unavailable for foreign-domiciled ADR filing schedules on NKTX vs SANA. Trailing 12-month operating profitability (NKTX 0.0% vs SANA 0.0%) and valuation multiples (NKTX N/M vs SANA N/M Forward P/E) are benchmarked directly in Pillar 4 below.

Pillar 4 Head-to-Head Fundamental & Valuation Matrix

Matrix Tally: NKTX (3) vs SANA (2)
Institutional Metric NKTX SANA Criterion Row Winner
Market Capitalization Scale $85.2M $605.3M Larger Scale SANA
Trailing P/E Ratio Valuation N/M N/M Lower Multiple Tie
Forward P/E Ratio Valuation N/M N/M Lower Multiple Tie
Revenue Growth (YoY) Growth +0.0% +0.0% Higher Growth Tie
Operating Margin (TTM) Profitability 0.0% 0.0% Higher Margin Tie
Net Profit Margin Profitability 0.0% 0.0% Higher Margin Tie
Return on Equity (ROE) Capital Efficiency -46.6% -79.5% Higher ROE NKTX
52-Week Range Position Momentum 4% ($1โ€“$4) 1% ($2โ€“$5) Stronger Trend NKTX
Beta / 30D Volatility Risk Regime 1.90ฮฒ ยท 116% Vol 1.82ฮฒ ยท 78% Vol Lower Realized Risk SANA
Unified Institutional Score Composite Signal 50.5 / 100 (HOLD) 44.3 / 100 (HOLD) Higher Composite NKTX

Pillar 5 Options Structure, IV Regime & Dealer Gamma Corridor

Full NKTX vs SANA Buy Guide
NKTX UNCLASSIFIED
0d in phase ยท OBV NEUTRAL
Put Wall Floor Pro Only
Call Wall Magnet Pro Only
IV Percentile <1st %ile
IV Regime Compressed (<25th %ile)
Live NKTX Put/Call Gamma Walls & dealer positioning signals require Pro. Unlock 14-Day Free Trial →
SANA BREAKDOWN
57d in phase ยท OBV NEUTRAL
Put Wall Floor Pro Only
Call Wall Magnet Pro Only
IV Percentile 4th %ile
IV Regime Compressed (<25th %ile)
Live SANA Put/Call Gamma Walls & dealer positioning signals require Pro. Unlock 14-Day Free Trial →

Pillar 6 90-Day Technical & R&D Innovation Disclosures

Corporate R&D & Foundry Tracker
Neither NKTX nor SANA registered frontier semiconductor/AI engineering publications in the trailing 90-day window; head-to-head edge is anchored on operating margin trajectory, valuation multiples, and options structure above.